Uncategorized
September 24, 2019

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Read More
Uncategorized
September 24, 2019

3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015

Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush…
Read More